uniQure (NASDAQ:QURE) Stock Price Target Lowered at HC Wainwright

uniQure (NASDAQ:QURE – Get Free Report) had its price objective decreased by stock analysts at HC Wainwright from $80.00 to $65.00 in a research report issued to clients and investors on Wednesday, Benzinga reports. The brokerage currently has a “buy” rating on the biotechnology company’s stock. HC Wainwright‘s price target indicates a potential upside of 212.80% from the stock’s previous close.

QURE has been the topic of several other research reports. Barclays cut shares of uniQure from an “overweight” rating to an “equal weight” rating and lowered their target price for the stock from $60.00 to $28.00 in a research note on Monday, October 5th. Wells Fargo & Company reissued an “overweight” rating and issued a $75.00 price target on shares of uniQure in a research note on Tuesday, September 29th. Wolfe Research raised shares of uniQure from a “peer perform” rating to an “outperform” rating and set a $65.00 price target on the stock in a research note on Wednesday, July 29th. Wall Street Zen upgraded shares of uniQure from a “sell” rating to a “hold” rating in a research report on Saturday, November 7th. Finally, William Blair raised shares of uniQure to a “strong-buy” rating in a research note on Wednesday, September 23rd. One research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $55.58.

Check Out Our Latest Stock Report on uniQure

uniQure Stock Down 5.0%

Shares of NASDAQ:QURE opened at $20.78 on Wednesday. The company has a quick ratio of 11.52, a current ratio of 11.52 and a debt-to-equity ratio of 0.17. uniQure has a 1 year low of $8.73 and a 1 year high of $51.72. The business’s 50 day moving average price is $28.55 and its 200-day moving average price is $29.66.

uniQure (NASDAQ:QURE – Get Free Report) last posted its quarterly earnings data on Wednesday, November 4th. The biotechnology company reported ($0.88) EPS for the quarter, beating the consensus estimate of ($0.92) by $0.04. uniQure had a negative return on equity of 96.34% and a negative net margin of 1,154.84%. The firm had revenue of $5.20 million during the quarter, compared to the consensus estimate of $6.17 million. On average, equities analysts anticipate that uniQure will post -3.83 earnings per share for the current year.

Institutional Trading of uniQure

Large investors have recently added to or reduced their stakes in the stock. Orbimed Advisors LLC raised its holdings in shares of uniQure by 189.7% during the 1st quarter. Orbimed Advisors LLC now owns 2,136,149 shares of the biotechnology company’s stock worth $34,926,000 after acquiring an additional 1,398,749 shares during the period. Two Seas Capital LP acquired a new position in shares of uniQure during the 3rd quarter valued at about $31,988,000. Siren L.L.C. purchased a new stake in shares of uniQure in the first quarter valued at about $16,350,000. Assenagon Asset Management S.A. grew its holdings in shares of uniQure by 249.9% in the second quarter. Assenagon Asset Management S.A. now owns 513,530 shares of the biotechnology company’s stock valued at $23,653,000 after purchasing an additional 366,781 shares during the period. Finally, Kalehua Capital Management LLC acquired a new stake in uniQure during the first quarter worth about $4,760,000. 78.83% of the stock is currently owned by hedge funds and other institutional investors.

About uniQure

(Get Free Report)

uniQure N.V. is a biotechnology company that develops gene therapies for serious genetic and other diseases. The company uses adeno-associated virus (AAV) vectors to deliver genetic material to patients’ cells, with research and development operations in the United States and the Netherlands. Its programs have targeted conditions including Huntington’s disease, epilepsy and hemophilia B. uniQure developed the gene therapy now known as Hemgenix for hemophilia B; it is commercialized by CSL Behring under a partnership.

See Also

Analyst Recommendations for uniQure (NASDAQ:QURE)

Receive News & Ratings for uniQure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for uniQure and related companies with MarketBeat.com's FREE daily email newsletter.